News

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable…

7 months ago

FDA expands XENOVIEW® indication to include children from six years of age

Increases number of eligible patients by approximately one millionDURHAM, NC and LONDON, June 02, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging…

7 months ago

SS Innovations to Ring the Nasdaq Opening Bell on Tuesday, June 3, 2025

FORT LAUDERDALE, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII),…

7 months ago

NewGen Announces Planned $30 Million Strategic Investment in Solana Digital Asset Staking

NewGen’s significant expansion of its digital asset portfolio demonstrates its continued commitment to the blockchain technology sectorBANGKOK, June 02, 2025…

7 months ago

TELA Bio Appoints Jeffrey Blizard as President

Company Further Strengthens Executive Leadership Team to Drive Next Phase of GrowthMALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA…

7 months ago

Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics…

7 months ago

Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025

Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical…

7 months ago

LogicMark, Inc. Common Stock to Commence Trading on OTC Markets as the Company Continues Advancing Growth Initiatives

LOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (the “Company”), a provider of personal emergency response systems (“PERS”), health…

7 months ago

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7…

7 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed…

7 months ago